The fact that our immune systems capture and destroy nanoparticles and the drugs they carry has been a problem in the field of nanomedicine for some time. But, in the fight against cancer, researchers are now attempting to exploit this problem to their advantage.

Researchers around the world are seeking to identify techniques that use nanoparticles in the treatment of disease. Such particles are about 100 nanometers—one thousandth of a millimeter—in diameter, and within them researchers are inserting large numbers of even smaller drug molecules.

Optimism for this approach in the treatment of various forms of cancer has been particularly great.

Prostate cancer is the most common non-skin cancer in men worldwide. According to international estimates about one in six men will get prostate cancer during their lifetime and worldwide, over 375,000 patients will die from it each year. Tumor resistance to current therapies plays an essential role in this and new approaches are therefore urgently needed.

Now an international research team from the University of Bern, Inselspital Bern and the University of Connecticut has identified a previously unknown weak spot in prostate cancer cells. This weak spot is possibly also present in other cancer cells. The study was led by Mark Rubin from the Department for Biomedical Research (DBMR) and Center for Precision Medicine (BCPM) at the University of Bern and Inselspital Bern, and Rahul Kanadia from the Department of Physiology and Neurobiology and the Institute for Systems Genomics at the University of Connecticut. The research results have been published in the journal Molecular Cell.

“We took a closer look at a certain molecular machine called the spliceosome,” explains Anke Augspach, lead author of the study and researcher from the Department for BioMedical Research (DBMR). “It plays an important role in the translation of genes into proteins. In this process, the spliceosome separates parts of the gene that are not needed for the production of the protein and fuses the other parts.”

Almost as soon as there were super-resolution microscopes, scientists pointed them towards molecular motors called kinesins. These proteins, powered by the molecular fuel ATP, drive crucial processes including cell division, cell signalling and intracellular transport by shuttling cargo along protein highways called microtubules. Researchers have long wanted to understand how these motors work, but to visualize them, scientists have had to slow them down or isolate them in simplified, in vitro systems.

Now, in papers published concurrently in Science, two teams working independently have used a super-resolution tool called MINFLUX to study the motor in near-real time at physiologically relevant concentrations of ATP. The first paper, led by MINFLUX’s inventor, Stefan Hell, who has a joint appointment at the Max Planck Institute (MPI) for Multidisciplinary Sciences in Göttingen and the MPI for Medical Research in Heidelberg, both in Germany, used a new instrument design to track the protein in 3D, revealing details about its motion¹. The second, led by biophysicist Jonas Ries at the European Molecular Biology Laboratory in Heidelberg, showed for the first time that MINFLUX is capable of tracking kinesin even amid the bustle of living cells².

“This technology requires a lot of different things to work, and it’s fun to see all of these things coming together,” says Michelle Digman, a biomedical engineer at the University of California, Irvine, who develops imaging strategies but was not involved in either study. “It seemed like a proof of concept to show that they’re able to track kinesin very precisely. And when you have the live cell system, that’s even more spectacular.”